The Impact of Glucocorticoid Replacement Regimens on Metabolic Outcome and Comorbidity in Hypopituitary Patients
The DOI matches its Crossref record; 44 of the 48 references it cites were found in a registry or an index.
Abstract
Background: Hypopituitary patients with untreated GH deficiency and patients on inappropriately high doses of glucocorticoid (GC) share certain clinical features. Objective: The aim of the study was to examine the influence of GC substitution on clinical characteristics in hypopituitary patients before and after GH replacement therapy. Method: A total of 2424 hypopituitary patients within the KIMS (Pfizer International Metabolic Database) were grouped according to ACTH status. Comparisons were performed between subjects on hydrocortisone (HC) (n = 1186), cortisone acetate (CA) (n = 487), and prednisolone/dexamethasone (n = 52), and ACTH-sufficient patients (AS) (n = 717) before and after 1 yr of GH treatment in terms of body mass index, waist and hip circumference, blood pressure, glucose, glycosylated hemoglobin (HbA1c), serum lipids, IGF-I, and comorbidity. Hydrocortisone equivalent (HCeq) doses were calculated, and measurements were adjusted for sex and age. Results: At baseline, the HC group had increased total cholesterol, triglycerides, waist circumference, and HbA1c, and the prednisolone/dexamethasone group had increased waist/hip ratio as compared with AS. After HCeq dose adjustment, the HC group retained higher HbA1c than the CA group. GC-treated patients showed a dose-related increase in serum IGF-I, body mass index, triglycerides, low-density lipoprotein cholesterol and total cholesterol levels. Subjects with HCeq doses less than 20 mg/d (n = 328) at baseline did not differ from AS in metabolic endpoints. The 1-yr metabolic response to GH was similar in all GC groups and dose categories. All new cases of diabetes (n = 12), stroke (n = 8), and myocardial infarction (n = 3) during GH treatment occurred in GC-treated subjects. Conclusion: HCeq doses of at least 20 mg/d in adults with hypopituitarism are associated with an unfavorable metabolic profile. CA replacement may have metabolic advantages compared with other GCs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Retrospective studies of patients taking higher doses of glucocorticoids in some cases, including prednisolone or dexamethasone, appear to show a tendency to adverse metabolic consequences including weight gain, dyslipidemia, and diabetes mellitus (102).”
From Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [102]
In the citing paper
“When patients cut their GC dose in half (from 20-30 mg to 10-15 mg HC daily), mean body weight decreased by 7.1 kg after 6-12 months (209).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [209]
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423 · cited 1×
“Serum total cholesterol (TC) (15), triglycerides (16), and high-density lipoprotein cholesterol (HDL-C) (17) were measured as previously described, and low-density lipoprotein cholesterol (LDL-C) was calculated by the Friedewald formula (18).”
MethodSerum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide.
Fossati, P., & Prencipe, L. (1982) · Clinical Chemistry · doi:10.1093/clinchem/28.10.2077 · Cited by 2,905 · cited 1×
“Serum total cholesterol (TC) (15), triglycerides (16), and high-density lipoprotein cholesterol (HDL-C) (17) were measured as previously described, and low-density lipoprotein cholesterol (LDL-C) was calculated by the Friedewald formula (18).”
MethodCholesterol determination in high-density lipoproteins separated by three different methods.
Lopes-Virella, M. F., Stone, P., Ellis, S., & Colwell, J. A. (1977) · Clinical Chemistry · doi:10.1093/clinchem/23.5.882 · Cited by 1,841 · cited 5×
“This study was carried out in Eu- First Published Online August 8, 2006 Abbreviations: AE, Adverse event; AS, ACTH-sufficient (patients); BMI, body mass index; BP, blood pressure; CA, cortisone acetate; CI, confidence interval; DHEA, dehydroepiandrostenedione; DHEAS, DHEA sulfate; DM, diabetes mellitus; DX, dexamethas…”
MethodInfluentialGlucocorticoid-Induced Osteoporosis: Pathogenesis and Management
Lukert, B. P., & Raisz, L. G. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-5-352 · Cited by 1,066
Association between premature mortality and hypopituitarism
Tomlinson, J., Holden, N., Hills, R., Wheatley, K., Clayton, R., Bates, A., Sheppard, M., & Stewart, P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04006-x · Cited by 1,006 · cited 1×
“This could explain some of the metabolic features and increased cardiovascular mortality associated with severe GHD (9).”
BackgroundThe natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“ease, with no safe lower dose threshold (38, 39).”
BackgroundDaily cortisol production rate in man determined by stable isotope dilution/mass spectrometry
ESTEBAN, N. V., LOUGHLIN, T., YERGEY, A. L., ZAWADZKI, J. K., BOOTH, J. D., WINTERER, J. C., & LORIAUX, D. L. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-1-39 · Cited by 481 · cited 8×
“Recently, a reduction in GC dose has been advocated because physiological cortisol production has been shown to be lower than previously thought (10).”
BackgroundInfluentialCanalis, E. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.10.3441 · Cited by 463
Brabant, G., von zur Mühlen, A., Wüster, C., Ranke, M. B., Kratzsch, J., Kiess, W., Ketelslegers, J.-M., Wilhelmsen, L., Hulthén, L., Saller, B., et al. (2003) · Hormone Research in Paediatrics · doi:10.1159/000071871 · Cited by 360 · cited 1×
“In subsequent years, a chemiluminescence immunoassay was used (Nichols Advantages system) (20).”
MethodSelf-citation
Cited by
Bornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1710 · Cited by 1,769
“Retrospective studies of patients taking higher doses of glucocorticoids in some cases, including prednisolone or dexamethasone, appear to show a tendency to adverse metabolic consequences including weight gain, dyslipidemia, and diabetes mellitus (102).”
BackgroundHormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Complications of Cushing's syndrome: state of the art
Pivonello, R., Isidori, A. M., De Martino, M. C., Newell-Price, J., Biller, B. M. K., & Colao, A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00086-3 · Cited by 641
Glucocorticoids and cardiovascular disease
Walker, B. R. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0455 · Cited by 529
Diagnosis and management of adrenal insufficiency
Bancos, I., Hahner, S., Tomlinson, J., & Arlt, W. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70142-1 · Cited by 467
Dynamics of ACTH and Cortisol Secretion and Implications for Disease
Lightman, S. L., Birnie, M. T., & Conway-Campbell, B. L. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa002 · Cited by 439
“…standard replacement therapy results in impaired health-related quality of life (211–216), adverse metabolic and cardiovascular risk profiles (217), increased levels of proinflammatory cytokines (218), and— most disabling for many patients—reduced activity, low motivation, and mental fatigue…”
BackgroundMechanisms of Glucocorticoid-Induced Insulin Resistance
Geer, E. B., Islam, J., & Buettner, C. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.10.005 · Cited by 392
Mortality in Patients with Pituitary Disease
Sherlock, M., Ayuk, J., Tomlinson, J. W., Toogood, A. A., Aragon-Alonso, A., Sheppard, M. C., Bates, A. S., & Stewart, P. M. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0033 · Cited by 392
Johannsson, G., Nilsson, A. G., Bergthorsdottir, R., Burman, P., Dahlqvist, P., Ekman, B., Engström, B. E., Olsson, T., Ragnarsson, O., Ryberg, M., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1926 · Cited by 329
“Oral hydrocortisone in daily divided doses is the most widely used glucocorticoid in cortisol replacement therapy (2, 3), but no formal studies of its safety and efficacy have been performed in patients with AI.”
InfluentialSelf-citationHigham, C. E., Johannsson, G., & Shalet, S. M. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30053-8 · Cited by 267
Self-citationReview: Replication of cortisol circadian rhythm: new advances in hydrocortisone replacement therapy
Chan, S., & Debono, M. (2010) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018810380214 · Cited by 243
“Patients with hypopituitarism on hydrocortisone equivalent doses greater than 20 mg/day have a higher body mass index (BMI), total cholesterol, low-density lipoprotein cholesterol (LDL-C) and triglycerides [Filipsson et al. 2006].”
BackgroundErichsen, M. M., Løvås, K., Fougner, K. J., Svartberg, J., Hauge, E. R., Bollerslev, J., Berg, J. P., Mella, B., & Husebye, E. S. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-0550 · Cited by 240
Hahner, S., Ross, R. J., Arlt, W., Bancos, I., Burger-Stritt, S., Torpy, D. J., Husebye, E. S., & Quinkler, M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00252-7 · Cited by 223
Pathophysiology of Dyslipidemia in Cushing’s Syndrome
Arnaldi, G., Scandali, V. M., Trementino, L., Cardinaletti, M., Appolloni, G., & Boscaro, M. (2010) · Neuroendocrinology · doi:10.1159/000314213 · Cited by 189
“On the contrary, a clear glucocorticoid dose-response relation with BMI, triglyceride, total cholesterol, and low-density lipoprotein (LDL) levels was found in 1,707 hypopituitary patients on glucocorticoid replacement treatment [”
BackgroundDiabetes in Cushing syndrome: basic and clinical aspects
Mazziotti, G., Gazzaruso, C., & Giustina, A. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.09.001 · Cited by 193
The Diagnosis and Management of Central Hypoadrenalism
Grossman, A. B. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0982 · Cited by 187
Sherlock, M., Reulen, R. C., Alonso, A. A., Ayuk, J., Clayton, R. N., Sheppard, M. C., Hawkins, M. M., Bates, A. S., & Stewart, P. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1097 · Cited by 185
Burman, P., Mattsson, A. F., Johannsson, G., Höybye, C., Holmer, H., Dahlqvist, P., Berinder, K., Engström, B. E., Ekman, B., Erfurth, E. M., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4059 · Cited by 184
“In support of a clinical relevance of lowered hydrocortisone replacement doses in hypopituitarism is the association between daily doses above 20 mg and a worsened cardiovascular risk profile (27), and a relation between hydrocortisone doses and cardiovascular mortality in acromegaly (28).”
Self-citationNewman, C. B., Blaha, M. J., Boord, J. B., Cariou, B., Chait, A., Fein, H. G., Ginsberg, H. N., Goldberg, I. J., Murad, M. H., Subramanian, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa674 · Cited by 172
Johannsson, G., Bergthorsdottir, R., Nilsson, A. G., Lennernas, H., Hedner, T., & Skrtic, S. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0170 · Cited by 173
Self-citationGazzaruso, C., Gola, M., Karamouzis, I., Giubbini, R., & Giustina, A. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2394 · Cited by 151
“In a large study, waist circumference decreased after 1 and 2 years of GH treatment, respectively, but remained unchanged after 5 years of GH substitution when compared with baseline (51, 52).”
ResultFractures and bone mineral density in adult women with 21-hydroxylase deficiency
Falhammar, H., Filipsson, H., Holmdahl, G., Janson, P.-O., Nordenskjöld, A., Hagenfeldt, K., & Thorén, M. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0744 · Cited by 151
Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management
Scaroni, C., Zilio, M., Foti, M., & Boscaro, M. (2017) · Endocrine Reviews · doi:10.1210/er.2016-1105 · Cited by 140
Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy
Debono, M., Ross, R. J., & Newell-Price, J. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-0874 · Cited by 135
“The important adverse effects of even modest excess glucocorticoid dosing on cardiovascular risk has been assessed in a recent large Scandinavian study in 2424 patients with hypopituitarism ( 20 ).”
BackgroundThe Glucocorticoid Receptor: Isoforms, Functions, and Contribution to Glucocorticoid Sensitivity
Lockett, J., Inder, W. J., & Clifton, V. L. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae008 · Cited by 135
Overall and cause-specific mortality in GH-deficient adults on GH replacement
Gaillard, R. C., Mattsson, A. F., Åkerblad, A.-C., Bengtsson, B.-Å., Cara, J., Feldt-Rasmussen, U., Kołtowska-Häggström, M., Monson, J. P., Saller, B., Wilton, P., et al. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-1028 · Cited by 130
Self-citationGiordano, R., Picu, A., Marinazzo, E., D’Angelo, V., Berardelli, R., Karamouzis, I., Forno, D., Zinnà, D., Maccario, M., Ghigo, E., et al. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04055.x · Cited by 122
Adrenal insufficiency: review of clinical outcomes with current glucocorticoid replacement therapy
Johannsson, G., Falorni, A., Skrtic, S., Lennernäs, H., Quinkler, M., Monson, J. P., & Stewart, P. M. (2015) · Clinical Endocrinology · doi:10.1111/cen.12603 · Cited by 122
Self-citationAn Update on Addison’s Disease
Barthel, A., Benker, G., Berens, K., Diederich, S., Manfras, B. J., Grüber, M., Kanczkowski, W., Kline, G. A., Kamvissi, V., Hahner, S., et al. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0804-2715 · Cited by 135
“Dexamethasone should not be used due to its non-physiological pharmacokinetic properties (long half-life) and the resulting risks for adverse metabolic effects such as dyslipidaemia, hyperglycaemia and diabetes [44, 45].”
BackgroundChabre, O., Goichot, B., Zénaty, D., & Bertherat, J. Y. (2017) · Annales d Endocrinologie · doi:10.1016/j.ando.2017.10.010 · Cited by 134
Kalafatakis, K., Russell, G. M., Harmer, C. J., Munafo, M. R., Marchant, N., Wilson, A., Brooks, J. C., Durant, C., Thakrar, J., Murphy, P., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714239115 · Cited by 119
“Several centers have confirmed that these treatment regimens result in impaired health-related quality of life (42–47), adverse metabolic and cardiovascular risk profiles (48), increased levels of proinflammatory cytokines (49), and reduced activity, low motivation, and mental fatigue, with associated high levels of u…”
BackgroundGrossman, A., Johannsson, G., Quinkler, M., & Zelissen, P. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0450 · Cited by 119
Self-citationModified-Release Hydrocortisone in Congenital Adrenal Hyperplasia
Merke, D. P., Mallappa, A., Arlt, W., Brac de la Perriere, A., Lindén Hirschberg, A., Juul, A., Newell-Price, J., Perry, C. G., Prete, A., Rees, D. A., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab051 · Cited by 109
“Age, y, median (range) 35 (19-61) 40 (19-68) 35 (20-67)”
BackgroundForss, M., Batcheller, G., Skrtic, S., & Johannsson, G. (2012) · BMC Endocrine Disorders · doi:10.1186/1472-6823-12-8 · Cited by 109
“; licensee BioMed Central Lt Commons Attribution License (http://creativec reproduction in any medium, provided the or factors [4,5] and reduced bone mineral density (mainly in female AI patients) [6-10], overly high glucocorticoid exposure is likely to occur at least during parts of the day/night.”
BackgroundResultSelf-citationGiordano, R., Guaraldi, F., Marinazzo, E., Fumarola, F., Rampino, A., Berardelli, R., Karamouzis, I., Lucchiari, M., Manetta, T., Mengozzi, G., et al. (2015) · Endocrine · doi:10.1007/s12020-015-0681-z · Cited by 105
“Our data are supported by previous studies performed in patients with secondary hypoadrenalism, suggesting that long-term glucocorticoid replacement therapy can cause dyslipidemia, with a clear relation between glucocorticoid dose and levels of total cholesterol and LDL-cholesterol [14, 29].”
Dalin, F., Nordling Eriksson, G., Dahlqvist, P., Hallgren, Å., Wahlberg, J., Ekwall, O., Söderberg, S., Rönnelid, J., Olcén, P., Winqvist, O., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2522 · Cited by 82
“with secondary adrenal insufficiency have shown that hydrocortisone doses $20 mg are associated with an increase in cardiovascular risk factors (37, 38).”
BackgroundSelf-citationMazziotti, G., Formenti, A. M., Frara, S., Roca, E., Mortini, P., Berruti, A., & Giustina, A. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0154 · Cited by 96
Glucocorticoid replacement and mortality in patients with nonfunctioning pituitary adenoma
Zueger, T., Kirchner, P., Herren, C., Fischli, S., Zwahlen, M., Christ, E., & Stettler, C. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2432 · Cited by 90
van der Klaauw, A. A., Biermasz, N. R., Feskens, E. J. M., Bos, M. B., Smit, J. W. A., Roelfsema, F., Corssmit, E. P. M., Pijl, H., Romijn, J. A., & Pereira, A. M. (2007) · European Journal of Endocrinology · doi:10.1530/eje-06-0699 · Cited by 86
“Patients mean maximal GH response during insulin-induced hypoglycaemia was only 0.3G0.4 mg/l (range 0.1‐1.6 mg/l), confirming the diagnosis of severe GHD ( 17 ) (Table 2).”
BackgroundInfluentialAdvances in the epidemiology, pathogenesis, and management of Cushing’s syndrome complications
Arnaldi, G., Mancini, T., Tirabassi, G., Trementino, L., & Boscaro, M. (2012) · Journal of Endocrinological Investigation · doi:10.1007/bf03345431 · Cited by 93
“439 ed with higher BMI and increased levels of triglycerides, total cholesterol, and LDL in patients with hypopituitarism (90).”
Giordano, R., Marzotti, S., Balbo, M., Romagnoli, S., Marinazzo, E., Berardelli, R., Migliaretti, G., Benso, A., Falorni, A., Ghigo, E., et al. (2009) · Journal of Endocrinological Investigation · doi:10.1007/bf03345773 · Cited by 84
Opioid-Induced Adrenal Insufficiency
Donegan, D., & Bancos, I. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.04.010 · Cited by 78
“Alternative glucocorticoid preparations with a longer half-life are available (prednisone, prednisolone, and dexamethasone) andmay improve compliance but aremore likely to be associated with excess glucocorticoid effects and greater suppression of endogenous cortisol release.(28) Adequacy of replacement is based on sy…”
BackgroundAttanasio, A. F., Jung, H., Mo, D., Chanson, P., Bouillon, R., Ho, K. K. Y., Lamberts, S. W. J., Clemmons, D. R., & for the HypoCCS International Advisory Board (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0448 · Cited by 74
“was found to be independent of glucocorticoid type and dose (30).”
BackgroundParkinson, C., Burman, P., Messig, M., & Trainer, P. J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1412 · Cited by 75
Danilowicz, K., Bruno, O. D., Manavela, M., Gomez, R. M., & Barkan, A. (2008) · Pituitary · doi:10.1007/s11102-008-0126-2 · Cited by 72
“The relatively modest excess in glucocorticoid replacement may have biological consequences: subjective health status in patients with hypoadrenalism is inversely proportionate to their glucocorticoid replacement dosage [20], and the ‘‘metabolic’’ abnormalities (BMI, waist circumference and lipids) in panhypopituitary…”
BackgroundCardiovascular risk factors in hypopituitary GH-deficient adults
Verhelst, J., & Abs, R. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0291 · Cited by 70
Hammarstrand, C., Ragnarsson, O., Hallén, T., Andersson, E., Skoglund, T., Nilsson, A. G., Johannsson, G., & Olsson, D. S. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0340 · Cited by 70
Self-citationAdrenal Cortical Insufficiency
Quinkler, M. O., Beuschlein, F., Hahner, S., Meyer, G., Schöfl, C., & Stalla, G. K. (2013) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2013.0882 · Cited by 82
Mazziotti, G., Porcelli, T., Bianchi, A., Cimino, V, Patelli, I., Mejia, C., Fusco, A., Giampietro, A., De Marinis, L., & Giustina, A. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0125 · Cited by 68
Novel strategies for hydrocortisone replacement
Debono, M., Price, J., & Ross, R. J. M. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.09.010 · Cited by 69
Rhythmicity matters: Circadian and ultradian patterns of HPA axis activity
Focke, C. M. B., & Iremonger, K. J. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110652 · Cited by 69
Ntali, G., Capatina, C., Fazal-Sanderson, V., Byrne, J. V., Cudlip, S., Grossman, A. B., Wass, J. A. H., & Karavitaki, N. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-0967 · Cited by 64
Gow, R., Koren, G., Rieder, M., & Van Uum, S. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04001.x · Cited by 60
Murray, R. D., Ekman, B., Uddin, S., Marelli, C., Quinkler, M., Zelissen, P. M. J., & the EU-AIR Investigators (2017) · Clinical Endocrinology · doi:10.1111/cen.13267 · Cited by 60
“1,14,18,22,23 The cardiometabolic profile of the patients in this analysis suggests the possibility of glucocorticoid over replacement, in that mean body mass index (BMI) was elevated, and a substantial proportion had diabetes or hypertension.”
BackgroundSimon, N., Castinetti, F., Ouliac, F., Lesavre, N., Brue, T., & Oliver, C. (2010) · Clinical Pharmacokinetics · doi:10.2165/11531290-000000000-00000 · Cited by 61
Quinkler, M., Ekman, B., Marelli, C., Uddin, S., Zelissen, P., Murray, R. D., & _, _. (2017) · Endocrine Connections · doi:10.1530/ec-16-0081 · Cited by 59
Novel insights into glucocorticoid replacement therapy for pediatric and adult adrenal insufficiency
Oprea, A., Bonnet, N., Pollé, O. G., & Lysy, P. A. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818821294 · Cited by 68
Webb, S. M., Strasburger, C. J., Mo, D., Hartman, M. L., Melmed, S., Jung, H., Blum, W. F., Attanasio, A. F., & on behalf of the HypoCCS International Advisory Board (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0713 · Cited by 59
“veillance databases (2, 33, 34) but provide important informa-”
BackgroundBurt, M. G., Willenberg, V., Petersons, C. J., Smith, M., Ahern, M. J., & Stranks, S. N. (2012) · Rheumatology · doi:10.1093/rheumatology/kes003 · Cited by 63
Metformin prevents metabolic side effects during systemic glucocorticoid treatment
Seelig, E., Meyer, S., Timper, K., Nigro, N., Bally, M., Pernicova, I., Schuetz, P., Müller, B., Korbonits, M., & Christ-Crain, M. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0653 · Cited by 60
Endocrine Disorder in Patients With Craniopharyngioma
Zhou, Z., Zhang, S., & Hu, F. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.737743 · Cited by 48
Therapy of adrenal insufficiency: an update
Falorni, A., Minarelli, V., & Morelli, S. (2012) · Endocrine · doi:10.1007/s12020-012-9835-4 · Cited by 61
“Accordingly, the highest dose of hydrocortisone/cortisone acetate must be administered in the morning at wakening, before breakfast, and the total daily dose should be subdivided in 2 or 3 doses [64, 66, 67] (Table 2).”
BackgroundRagnarsson, O., & Johannsson, G. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0534 · Cited by 51
Self-citationQuality of Life in Craniopharyngioma: A Systematic Review
Castle-Kirszbaum, M., Shi, M. D. Y., & Goldschlager, T. (2022) · World Neurosurgery · doi:10.1016/j.wneu.2022.05.038 · Cited by 49
Werumeus Buning, J., van Faassen, M., Brummelman, P., Dullaart, R. P. F., van den Berg, G., van der Klauw, M. M., Kerstens, M. N., Stegeman, C. A., Muller Kobold, A. C., Kema, I. P., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2216 · Cited by 50
Central adrenal insufficiency: open issues regarding diagnosis and glucocorticoid treatment
Ceccato, F., & Scaroni, C. (2019) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2018-0824 · Cited by 49
Filipsson, H., & Johannsson, G. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0319 · Cited by 50
Self-citationGrapefruit juice and licorice increase cortisol availability in patients with Addison's disease
Methlie, P., Husebye, E. E. S., Hustad, S., Lien, E. A., & Løvås, K. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0518 · Cited by 50
What is the best long‐term management strategy for patients with primary adrenal insufficiency?
Quinkler, M., & Hahner, S. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04103.x · Cited by 50
Tohti, M., Li, J., Zhou, Y., Hu, Y., Yu, Z., & Ma, C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0119621 · Cited by 49
“Other studies reported that high dose of cortisol replacement therapy was associated with unfavorable metabolic profile, higher intraocular pressure levels[27, 28].”
ResultNilsson, A. G., Marelli, C., Fitts, D., Bergthorsdottir, R., Burman, P., Dahlqvist, P., Ekman, B., Engström, B. E., Olsson, T., Ragnarsson, O., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0327 · Cited by 49
Self-citationMazziotti, G., Formenti, A., Frara, S., Maffezzoni, F., Doga, M., & Giustina, A. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0860-9 · Cited by 50
Bergthorsdottir, R., Ragnarsson, O., Skrtic, S., Glad, C. A. M., Nilsson, S., Ross, I. L., Leonsson-Zachrisson, M., & Johannsson, G. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01324 · Cited by 49
Self-citationGiordano, R., Marzotti, S., Berardelli, R., Karamouzis, I., Brozzetti, A., D'Angelo, V., Mengozzi, G., Mandrile, G., Giachino, D., Migliaretti, G., et al. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04439.x · Cited by 47
Adrenal fatigue does not exist: a systematic review
Cadegiani, F., & Kater, C. E. (2016) · BMC Endocrine Disorders · doi:10.1186/s12902-016-0128-4 · Cited by 52
Adrenal crises in older patients
Rushworth, R. L., Torpy, D. J., & Falhammar, H. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30122-4 · Cited by 48
Ragnarsson, O., Mattsson, A. F., Monson, J. P., Filipsson Nyström, H., Åkerblad, A.-C., Kołtowska-Häggström, M., & Johannsson, G. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0397 · Cited by 46
Self-citationOlsson, D. S., Bryngelsson, I., & Ragnarsson, Ó. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0173 · Cited by 49
Skov, J., Sundström, A., Ludvigsson, J. F., Kämpe, O., & Bensing, S. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02298 · Cited by 44
“Studies of secondary adrenal insufficiency, however, have reported adverse metabolic profiles and increased mortality for patients using higher glucocorticoid replacement doses (15, 16).”
BackgroundZimmermann, A., Sido, P. G., Schulze, E., Al Khzouz, C., Lazea, C., Coldea, C., & Weber, M. M. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03518.x · Cited by 45
On behalf of the Italian Society of Endocrinology, Isidori, A. M., Arnaldi, G., Boscaro, M., Falorni, A., Giordano, C. S. D. S., Giordano, R., Pivonello, R., Pozza, C., Sbardella, E., et al. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01146-y · Cited by 50
“, it was shown that adults with hypopituitarism receiving HC were more prone to development of an adverse metabolic profile than patients using cortisone acetate [65].”
BackgroundApproach to the Patient With Glucocorticoid-induced Adrenal Insufficiency
Borresen, S. W., Klose, M., Glintborg, D., Watt, T., Andersen, M., & Feldt‐Rasmussen, U. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac151 · Cited by 47
Baroni, M. G., Giorgino, F., Pezzino, V., Scaroni, C., & Avogaro, A. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0404-6 · Cited by 41
“This approach, however, causes adrenal insufficiency, and the subsequent treatment with glucocorticoids as replacement therapy may worsen the metabolic complications of Cushing’s syndrome [115, 116] in some patients.”
BackgroundNilsson, A. G., Bergthorsdottir, R., Burman, P., Dahlqvist, P., Ekman, B., Engström, B. E., Ragnarsson, O., Skrtic, S., Wahlberg, J., Achenbach, H., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0067 · Cited by 38
“The minimal changes in serum lipids with DR-HC are in contrast to standard glucocorticoid therapy at doses of ≥ 20 mg/day, which has been shown to be associated with an adverse cardiovascular risk profile (10).”
Self-citationIncreased Cardiovascular Risk in Patients with Adrenal Insufficiency: A Short Review
Rahvar, A., Haas, C. S., Danneberg, S., & Harbeck, B. (2017) · BioMed Research International · doi:10.1155/2017/3691913 · Cited by 42
Metabolic Syndrome in Hypopituitarism
Miljić, D., & POPOVIC, V. M. (2018) · Frontiers of hormone research · doi:10.1159/000485997 · Cited by 42
Werumeus Buning, J., Brummelman, P., Koerts, J., Dullaart, R. P. F., van den Berg, G., van der Klauw, M. M., Sluiter, W. J., Tucha, O., Wolffenbuttel, B. H. R., & van Beek, A. P. (2016) · Neuroendocrinology · doi:10.1159/000442985 · Cited by 37
Wentworth, J. M., Gao, N., Sumithran, K. P., Maartens, N. F., Kaye, A. H., Colman, P. G., & Ebeling, P. R. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02995.x · Cited by 36
Rushworth, R., & Torpy, D. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0034-1395680 · Cited by 37
Iatrogenic adrenal insufficiency in adults
Martin‐Grace, J., Tomkins, M., O’Reilly, M., & Sherlock, M. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00929-x · Cited by 40
Current Challenges and Future Directions in the Assessment of Glucocorticoid Status
Clarke, S. A., Eng, P. C., Comninos, A. N., Lazarus, K., Choudhury, S., Tsang, C., Meeran, K. M., Tan, T., Dhillo, W. S., & Abbara, A. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae016 · Cited by 38
Assessment of glucocorticoid therapy with salivary cortisol in secondary adrenal insufficiency
Ceccato, F., Albiger, N., Reimondo, G., Frigo, A. C., Ferasin, S., Occhi, G., Mantero, F., Terzolo, M., & Scaroni, C. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0534 · Cited by 35
“exposure in patients treated with CA or HC in association with rhGH therapy, which inhibits the metabolism of cortisone into cortisol (8, 9, 23).”
Höybye, C., Ragnarsson, O., Jönsson, P. J., Koltowska-Häggström, M., Trainer, P., Feldt-Rasmussen, U., & Biller, B. M. K. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0836 · Cited by 34
Hypopituitarism and Central Diabetes Insipidus
Devin, J. K. (2012) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2012.06.001 · Cited by 33
Circadian and ultradian rhythms: Clinical implications
Lightman, S. L., & Conway-Campbell, B. L. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13795 · Cited by 35
“Studies have described impaired health-related quality of life [81–85], reduced activity, low motivation and mental fatigue [82, 83, 86–88], as well as increased metabolic, cardiovascular and proin-flammatory cytokine profile s [89, 90].”
Noppe, G., van Rossum, E. F. C., Vliegenthart, J., Koper, J. W., & van den Akker, E. L. T. (2014) · Clinical Endocrinology · doi:10.1111/cen.12551 · Cited by 29
Bariatric Surgery in Hypothalamic Obesity
Bingham, N. C., Rose, S. R., & Inge, T. H. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00023 · Cited by 36
Replacement therapy for Addison's disease: recent developments
Løvås, K., & Husebye, E. S. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.4.497 · Cited by 32
“Furthermore, there is increasing evidence that such treatment confers higher risk of long-term adverse metabolic effects compared with the natural glucocorticoids [17,18,61,62] .”
BackgroundDual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life
Mongioì, L. M., Condorelli, R. A., Vignera, S. L., & Calogero, A. E. (2017) · Endocrine Connections · doi:10.1530/ec-17-0368 · Cited by 33
Ragnarsson, O., Nyström, H. F., & Johannsson, G. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04174.x · Cited by 31
Self-citation
Metadata
- Authors
- Filipsson, H., Monson, J. P., Koltowska-Häggström, M., Mattsson, A., & Johannsson, G.
- Affiliations
- Department of Endocrinology (H.F., G.J.), Sahlgrenska Academy at Gothenburg’s University, SE-413 45 Gothenburg, Sweden
- St Bartholomew's Hospital (GB)
- KIGS/KIMS/ACROSTUDY Medical Outcomes (M.K.-H., A.M.), Endocrine Care, Pfizer, SE-191 90 Sollentuna, Sweden
- Pfizer (Sweden) (SE)
- University of Gothenburg (SE)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-10-01
- Volume
- 91
- Issue
- 10
- Pages
- 3954-3961
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2137769079
- Cited by
- 321
- References
- 48
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 25 · 2023: 12 · 2022: 13 · 2021: 17 · 2020: 24 · 2019: 18 · 2018: 16 · 2017: 16 · 2016: 25 · 2015: 20 · 2014: 23 · 2013: 12 · 2012: 19
- FWCI
- 7.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Chalmers Research (Chalmers University of Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- hypopituitarism, glucocorticoid replacement therapy, cortisol, cortisone acetate, prednisolone, dexamethasone, growth hormone replacement therapy, metabolic profile, body mass index, waist circumference, serum lipids, HbA1c, insulin-like growth factor I, diabetes mellitus, stroke, myocardial infarction, comorbidities, glucocorticoid dose
- MeSH terms
- Adrenocorticotropic Hormone, Adult, Aged, Female, Glucocorticoids, Humans, Hypopituitarism, Insulin-Like Growth Factor I, Lipids, Male, Middle Aged, Risk Factors, Growth Hormone, Comorbidity, Body Mass Index, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.